Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised,...

Keywords

SABR volatility modelAblative caseMedicineRadiation therapyStandard of careOpen labelPalliative careRadiosurgeryRandomized controlled trialSurgery

Affiliated Institutions

Related Publications

The National Lung Screening Trial: Overview and Study Design

Constantine A. Gatsonis , Denise R. Aberle , Christine D. Berg +97 more

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older c...

2010 Radiology 1227 citations

UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer

David Baldwin , Stephen W. Duffy , Nicholas Wald +3 more

The UK Lung Screen (UKLS) is a randomised controlled trial of the use of low-dose multidetector CT for lung cancer screening. It completed the Health Technology Appraisal (HTA)-...

2011 Thorax 226 citations

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo , Richard S. Finn , Shukui Qin +19 more

2018 The Lancet 5118 citations

Publication Info

Year: 2019
Type: article
Volume: 393
Issue: 10185
Pages: 2051-2058
Citations: 1754
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1754

OpenAlex

Cite This

APA Style

                            
                                
                                    David A. Palma, 
                                
                                    Robert Olson, 
                                
                                    Stephen Harrow
                                
                                et al.
                            
                            (2019). 
                            Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. 
                            The Lancet
                            , 393
                            (10185)
                            , 2051-2058.
                            https://doi.org/10.1016/s0140-6736(18)32487-5
                        

Identifiers

DOI: 10.1016/s0140-6736(18)32487-5